Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
SMMT
#671
Summit Therapeutics Inc. Common Stock
16.590
0
+7.66%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
+7.66%
Aylık değişim
+4.60%
6 aylık değişim
-16.47%
Yıllık değişim
-16.47%
Önceki kapanış
15.410
0
Open
16.590
0
Bid
Ask
Low
16.590
0
High
16.590
0
Hacim
263
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
SMMT
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
737.45 M
737.68 M
742.67 M
742.85 M
744.44 M
775.37 M
—
Valuation ratios
Enterprise value
16.06 B
13.06 B
14.11 B
15.51 B
15.14 B
13.34 B
58.1 B
Price to earnings ratio
84.23
-57.56
-56.74
-21.07
-16.66
-12.15
-106.61
Price to sales ratio
34.16 K
—
-54.18 K
-49.17 K
381.4 K
21.44 K
299.49 K
Price to cash flow ratio
-134.64
-90.23
-80.74
-75.41
-56.49
-40.5
-253.14
Price to book ratio
20.53
32.98
10.23
10.86
12.79
19.85
53.73
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.11
0.14
0.16
1.75
0.89
0.29
3.09
Return on equity %
0.13
0.16
0.18
2.18
1.21
0.33
3.9
Return on invested capital %
—
—
—
—
—
-1 405.9
—
Gross margin %
—
100
100
100
100
100
400
Operating margin %
—
-11.01 K
-70.27 K
-285.55 K
-64.6 K
803.4 K
382.99 K
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
-10.27 K
66.22 K
284.28 K
64.03 K
-782.76 K
-368.23 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
8.31
10.15
10.63
5.13
3.8
9.87
29.42
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
-0
0
0
0
-0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0
0
—
—
—
—
—
Long term debt to total equity ratio
0
0
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.04
0.07
0.08
0.09
0.13
0.14
0.43
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
0.68
0.57
0.49
0.4
0.32
0.95
2.17
Net current asset value per share
0.69
0.59
0.5
0.42
0.33
0.96
2.22
Tangible book value per share
0.61
0.54
0.46
0.35
0.26
0.88
1.95
Working capital per share
0.61
0.53
0.46
0.34
0.24
0.87
1.9
Book value per share
0.61
0.54
0.47
0.35
0.26
0.88
1.96
Haberler
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View
H.C. Wainwright, Summit Therapeutics hisse hedefini düşürdü
H.C. Wainwright cuts Summit Therapeutics stock price target on China trial timing uncertainty
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus
Citizens, Summit Therapeutics hissesi için hedefini korudu
Citizens reiterates Summit Therapeutics stock rating on pipeline expansion
Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript
Summit Therapeutics Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:SMMT) 2026-02-23
Summit’ın 4Ç 2025 sunumu: klinik başarılar %389’luk EPS kaybını dengeleyemedi
Summit Q4 2025 slides: clinical wins offset by 389% EPS miss
Earnings call transcript: Summit Therapeutics Q4 2025 reports significant EPS miss
Summit Therapeutics ilerlemeye rağmen kazanç kaybıyla düştü